Peptidic Diagnostic Compositions for TFRC/RAGE Blood-Brain Barrier Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for targeting therapeutic and diagnostic agents to specific sites, such as the brain, face challenges in effectively crossing the blood-brain barrier and achieving site-specific delivery, leading to inefficiencies and potential toxicity.
Innovation Solution
A chemically modified polypeptide conjugate, specifically the peptide Gly-Tyr-Arg-Pro-Val-His-Asn-Ile-Arg-Gly-His-Trp-Ala-Pro-Gly, or derivatives with at least 80% identity, is used to target both transferrin receptor (TFRC) and receptor for advanced glycation end products (RAGE), allowing for binding and internalization into cells, forming a core-shell nanoparticle structure for targeted drug or diagnostic delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a particulate drug carrier system is used for drug delivery and targeting, then protection against drug degradation is improved, but the ability to cross the blood-brain barrier deteriorates
Solution Approach 1:
The drug carrier system is segmented into multiple functional components: a core particle for drug encapsulation, surface-modifying ligands for BBB recognition, and targeting moieties for specific cell binding. This segmentation allows each component to perform its specialized function - the core provides protection while the surface modifications enable BBB penetration
Solution Approach 2:
Surface-modifying ligands act as intermediaries between the drug carrier system and the blood-brain barrier. These ligands mediate the interaction by providing recognition signals that facilitate BBB crossing, bridging the gap between the protected drug core and the barrier structure
2Object-affected harmful factors
If site-specific targeting of drugs is achieved, then drug-induced toxicity is reduced, but the complexity of the delivery system increases
Solution Approach 1:
The drug carrier system is designed with multi-functionality to reduce complexity: the same core particle structure can deliver different drugs, while universal targeting ligands can direct various carriers to the same BBB target. This universality allows one platform to serve multiple therapeutic purposes without requiring completely different delivery systems for each application
Solution Approach 2:
Multiple functions are merged into a single integrated carrier system: drug encapsulation, BBB penetration, and cell-specific targeting are combined in one structure. This merging eliminates the need for separate steps or systems for each function, reducing overall complexity while achieving site-specific targeting to minimize toxicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptide conjugate efficiently crosses the blood-brain barrier and targets cells expressing TFRC and RAGE, enhancing the delivery of therapeutic and diagnostic agents to the brain while minimizing toxicity and improving efficacy.
Implementation Method 1
targeting at least two receptors... binding and internalization into cells
Implementation Method 2
internalization and/or transcytosis of the bound carrier... binding and internalization into cells
Implementation Method 3
Encapsulation or incorporation of drug molecules in certain drug carriers (e.g., liposomes) can further attain protection against drug degradation
Data Source
AI summary
A polypeptide conjugate for use in a method for binding and/or internalization of the polypeptide conjugate to a mammalian cell having a transferrin receptor (TFRC) and/or receptor for advanced glycation end products (RAGE). The polypeptide conjugate may be used in a method for targeting of a drug delivery system or diagnostic delivery system.